On August 4, 2020 Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with an extensive pipeline of checkpoint antibodies, cell therapy, adjuvants, and vaccines designed to activate immune response to cancers and infections, reported that Dr. Jennifer Buell, President and COO of Agenus will present on Targeting Myeloid Cells in the Tumor Microenvironment at the upcoming William Blair Biotech Focus Conference 2020 (Press release, Agenus, AUG 4, 2020, View Source [SID1234562820]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Agenus Logo

Date: Tuesday, August 4, 2020

Webcast Info: View Source

Title: Targeting Myeloid Cells in Tumor Microenvironment

Time: 11:00AM – 12:00 PM

Keynote Speaker:
Miriam Merad, M.D., Ph.D., – Chair Professor in Cancer Immunology and Director of the Precision Immunology Institute Mount Sinai School of Medicine

Presentations:
Agenus Inc.
Jennifer Buell, Ph.D. – President and Chief Operating Officer

Codiak Biosciences
Douglas Williams, Ph.D. – President and Chief Executive Officer